Trump’s ‘America First’ Vaccine Agenda May Leave Us Last

By using the usual patent monopoly framework rather than international open-source collaboration, the coronavirus vaccine may prove both elusive and more costly for Americans.

by

The American Prospect depends on reader support

If you are scraping by right now, please don’t give us anything. But if you have the ability to support independent, non-profit journalism, we are so grateful. Your voluntary contribution helps keep this website paywall-free. You can sign up as a subscriber with a range of benefits, including an opt-in to receive the print magazine by mail.

Click to View Subscriber Levels: IDEAS, POLITICS & POWER